clinmed.2021-0488.full.pdf (89.8 kB)
VITT, COVID-19 and the Expert Haematology Panel: the story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme
Version 2 2023-06-12, 08:10
Version 1 2023-06-10, 01:39
journal contribution
posted on 2023-06-12, 08:10 authored by Timothy ChevassutTimothy Chevassut, Beverley J Hunt, Sue PavordThe COVID-19 pandemic has resulted in the development of highly effective vaccines that provide hope to the global community for reducing the spread of SARS-CoV-2 and limiting the mortality and morbidity caused by the disease. These vaccines have been produced using differing technologies, taken through clinical trials, and rolled out across the UK at unprecedented speed. However, the recent emergence of rare cases of life-threatening thrombosis in association with thrombocytopenia has threatened to derail one particular vaccine, the Oxford AstraZeneca ChAdOx1 vaccine, upon which many countries are dependent for their vaccination programmes. The story of how this situation has been managed in the UK at the height of the vaccine roll-out represents a remarkable collective endeavour on the part of the haematology community, working closely with other acute medical and surgical professionals within the NHS and the UK health regulatory bodies, to provide rapid expert guidance that has saved lives and helped keep the national vaccination programme on track.
History
Publication status
- Published
File Version
- Published version
Journal
Clinical MedicineISSN
1470-2118Publisher
Royal College of PhysiciansExternal DOI
Issue
6Volume
21Page range
1-3Event location
EnglandDepartment affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2021-11-08First Open Access (FOA) Date
2021-11-08First Compliant Deposit (FCD) Date
2021-11-08Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC